Literature DB >> 30178833

Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis.

M Liang1, J Zhao.   

Abstract

OBJECTIVE: To investigate the protein expressions of steroid receptor coactivator amplified in breast cancer 1 (AIB1), apoptosis-related protein p53 and B-cell lymphoma-2 (Bcl-2) in epithelial ovarian cancer; to analyze the correlations among the expressions of these three proteins; to explore their correlations with the clinical pathological features and prognosis.
MATERIALS AND METHODS: Immunohistochemistry streptavidin-peroxidase (IHC-SP) method was performed to detect the positive protein expressions of AIB1, Bcl-2, and p53 in the pathological sections of normal ovarian tissues, benign ovarian epithelial tumor, and epithelial ovarian cancer, thereby analyzing the protein expression rates of these genes in different pathological stages, lymphatic metastasis and postoperative recurrent ovarian cancer, and carrying out the correlation analysis of these three proteins.
RESULTS: Positive protein expressions of AIB1, Bcl-2, and p53 were identified in the epithelial ovarian cancer tissues, and with an increase in the tumor staging of ovarian cancer, we found that the positive protein expression rate was gradually augmented. Particularly in ovarian cancer with lymphatic metastasis and postoperative recurrence, the positive expression rate was almost 100%. The protein expression of AIB1 was positively correlated with those of the p53 and Bcl-2.
CONCLUSIONS: We showed that positive expressions of AIB1, Bcl-2, and p53 in ovarian cancer are closely correlated with the pathological staging, metastasis, and recurrence, and the positive protein expression suggests a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178833     DOI: 10.26355/eurrev_201808_15708

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 2.  Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review).

Authors:  Jing Yuan; Hua Lan; Xiaoyan Jiang; Da Zeng; Songshu Xiao
Journal:  Int J Mol Med       Date:  2020-07-29       Impact factor: 4.101

3.  High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer.

Authors:  Lin Tan; Ling Sha; Ning Hou; Mei Zhang; Qian Ma; Chuanbing Shi
Journal:  Biosci Rep       Date:  2019-06-18       Impact factor: 3.840

Review 4.  Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements.

Authors:  Salima Akter; Md Ataur Rahman; Mohammad Nazmul Hasan; Hajara Akhter; Priya Noor; Rokibul Islam; Yoonhwa Shin; M D Hasanur Rahman; Md Shamim Gazi; Md Nazmul Huda; Nguyen Minh Nam; Jinwook Chung; Sunhee Han; Bonglee Kim; Insug Kang; Joohun Ha; Wonchae Choe; Tae Gyu Choi; Sung Soo Kim
Journal:  Cells       Date:  2022-02-13       Impact factor: 6.600

Review 5.  Potential relationship between Sirt3 and autophagy in ovarian cancer.

Authors:  Yuchuan Shi; Runhua He; Yu Yang; Yu He; Lei Zhan; Bing Wei
Journal:  Oncol Lett       Date:  2020-08-26       Impact factor: 2.967

6.  Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.

Authors:  Ting Guo; Chao Gu; Bin Li; Congjian Xu
Journal:  Aging (Albany NY)       Date:  2021-08-05       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.